Screener
CONMED CNMD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by CONMED in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: CONMED’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000816956-26-000102
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $37,328 | $40,817 |
| Accounts receivable, net | 239,770 | 247,830 |
| Inventories | 360,179 | 355,544 |
| Prepaid expenses and other current assets | 38,388 | 28,669 |
| Total current assets | 675,665 | 672,860 |
| Property, plant and equipment, net | 110,144 | 113,331 |
Item 1. Financial Statements (unaudited)
FAQ
- What is CONMED's cash & equivalents?
- CONMED (CNMD) reported cash & equivalents of $37.33M in Q2 2026.
- How has CONMED's cash & equivalents changed year-over-year?
- CONMED's cash & equivalents increased by 10.0% year-over-year, from $33.94M to $37.33M.
- What is the long-term trend for CONMED's cash & equivalents?
- Over 5 years (2020 to 2025), CONMED's cash & equivalents has grown at a 8.3% compound annual growth rate (CAGR), from $27.36M to $40.82M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about CONMED's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude